According to Fox News, a bipartisan group of more than 50 lawmakers urged CMS Administrator Mehmet Oz to abandon a proposed fixed-dose combination policy tied to Medicare's drug price negotiation program. The policy stems from the 2022 Inflation Reduction Act. The Trump administration introduced this version in 2026.
The rule creates a perverse incentive. If drugmakers believe combining or improving an existing medicine will trigger harsher Medicare pricing, they'll spend less on follow-on therapies. In oncology, that means fewer incremental advances. Better dosing. Fewer side effects. Longer survival. Patients with limited options lose out.
CMS now has a clear bipartisan signal this isn't a routine partisan dispute. The agency must decide whether to rewrite the policy before finalizing the rule, or defend a Biden-era framework at the cost of a public fight over cancer drug innovation.
This is what happens when Washington drafts price controls with a broad brush and then discovers medicine is full of edge cases. A policy sold as savings becomes a tax on incremental innovation. In oncology, where "improved" often means survival gains or easier dosing for people already out of good options, that's not a technicality. It's the difference between a therapy and a dead end.
Filed to the Politics desk · Sep 29